熱門資訊> 正文

Anavex生命科学GAAP每股收益为-0.06美元

2026-07-30 20:14

Anavex Life Sciences Corp.(AVXL) 0

Anavex Life Sciences press release (AVXL): Q2 GAAP EPS of -$0.06.
Preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102.6 million as of September 30, 2025. The Company expects the cash balance at the end of the second fiscal quarter of 2026 to fund operations into mid-to-late fiscal 2028.

More on Anavex Life Sciences

Anavex Life Sciences: Waiting On Validation As Blarcamesine Shows Some Promise
Anavex Life Sciences receives Nasdaq delinquency notice
Anavex slips after CEO transition
Seeking Alpha’s Quant Rating on Anavex Life Sciences
Historical earnings data for Anavex Life Sciences

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。